Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 14, keine Gesamtzahl für „less“
Suchtreffer
Begriffe & Kennungen
Jakavi · 4.8 · 44 Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients in REACH2
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients in REACH3 an
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 18.1% of patients in REACH3 an
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 19.4% of patients.
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 29.4% of patients in REACH2 an
Eintrag öffnenJakavi · 4.8 · Discontinuation due to adverse events, regardless of causality, was observed in 30.0% of patients.
Eintrag öffnenJakavi · 4.8 · In the randomised period of the pivotal studies, anaemia was less frequent in PV patients than in MF patients
Eintrag öffnenJanumet · 4.8 · Among these patients, adverse events reported regardless of causal relationship to medicinal product occurring
Eintrag öffnenJemperli · 4.8 · Of the 605 patients treated with dostarlimab monotherapy, 51.6 % were under 65 years, 36.9 % were 65 to less t
Eintrag öffnenKaftrio · 4.8 · 46 During study 445-106 in patients aged 6 to less than 12 years, the incidence of maximum transaminase (ALT o
Eintrag öffnenKaftrio · 4.8 · During study 445-106 in patients aged 6 to less than 12 years, the incidence of maximum transaminase (ALT or A
Eintrag öffnenKaftrio · 4.8 · During study 445-111 in patients aged 2 to less than 6 years, the incidence of maximum transaminase (ALT or AS
Eintrag öffnenKaftrio · 4.8 · During study 445-111 in patients aged 2 to less than 6 years, the incidence of maximum transaminase (ALT or AS
Eintrag öffnenKaletra · 4.5 · Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/r
Eintrag öffnenKaletra · 4.5 · Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/r
Eintrag öffnenKaletra · 4.5 · Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/r
Eintrag öffnenKalydeco · 4.8 · 45 6 years of age, 61 patients between 6 to less than 12 years of age and 94 patients between 12 to less than
Eintrag öffnenKalydeco · 4.8 · 46 During study 445-106 in patients aged 6 to less than 12 years, the incidence of maximum transaminase (ALT o
Eintrag öffnenKalydeco · 4.8 · During study 445-106 in patients aged 6 to less than 12 years, the incidence of maximum transaminase (ALT or A
Eintrag öffnenKalydeco · 4.8 · During study 445-111 in patients aged 2 to less than 6 years, 15 (20.0%) subjects had at least 1 rash event, 4
Eintrag öffnen